About Mitochondrial Medicine 2023 and Continuing Medical Education

On June 28-July 1, 2023, the United Mitochondrial Disease Foundation (UMDF) hosted Mitochondrial Medicine 2023 (MitoMed23) - This was a four-day scientific meeting conference directed toward the scientist and clinician interested in all aspects of mitochondrial science. The content of this educational program was determined by rigorous assessment of educational needs and includes surveys, program feedback, expert faculty assessment, literature review, medical practice, and new medical knowledge.  

Select courses from MitoMed2023 are available for Continuing Medical Education credits as enduring material. The UMDF proudly hosts annual symposia, bringing together the mitochondrial medicine community. For more information about UMDF, visit www.umdf.org/symposium.

Continuing Medical Education Course Information

 

COURSE DESCRIPTION

The United Mitochondrial Disease Foundation and PeerPoint Medical Education Institute have joined efforts to sponsor and organize a CME-accredited activity. Mitochondrial diseases are more common than previously recognized and mitochondrial pathophysiology is now a recognized part of many disease processes, including heart disease, cancer, AIDS, diabetes and autism.  This live meeting is directed toward the scientist and clinician interested in obtaining a comprehensive update on mitochondrial medicine. The format will include didactic lectures from invited experts intermixed with rigorous discussion. There will be ample time for questions and answers throughout the program. 

 

TARGET AUDIENCE

Neurologists, Geneticists, Researchers/Scientists, Pediatrics, Internal Medicine, Nephrologists, Cardiologists, Endocrinologists, Genetic Counselors, Advanced Practice Nurses, Physicians Assistants, RNs, Occupational Therapy, Physical Therapy and Speech-Language Pathology, Nutritional Therapy, and Residents/Fellows/Students.

 

ACCREDITATION AND DESIGNATION STATEMENTS

Live Activity:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of 19.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Enduring Activity:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 14.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Live activity dates: June 28, 2023 – July 1, 2023

Enduring activity dates: December 22, 2023 – December 22, 2026


LEARNING OBJECTIVES

  • Define the role of the mitochondrion in regulating the innate immune system.
  • Recognize the importance of mitochondrial-mediated inflammation in diseases.
  • Describe the previously unrecognized functions encoded by the mtDNA.
  • Indicate some of the disease implications of variation in these novel mtDNA functions.
  • Review the viruses and viral gene products that interact with the mitochondrion.
  • Explain the effects of viral infections on modulating mitochondria disease outcomes.
  • Discuss the functional consequences of altered mitochondrial metabolism in disease.
  • Appraise the mechanisms the cell uses in the regulation of mitochondrial metabolism.
  • Communicate the current status of biomarkers used in the diagnostic evaluation of mitochondrial disease
  • Cite the potential use of biomarkers to evaluate outcome measures in therapeutic trials for mitochondrial disease
  • Compare the current approaches for genetic treatment of nDNA & mtDNA mitochondrial disease.
  • Analyze the current status of germline mtDNA gene therapy.
  • Assess how mitochondria are exchanged between cells.
  • Discover how mitochondrial transplantation is used to treat disease.
  • Interpret mtFASII disease through preclinical models.
  • Contrast the therapeutic approaches to treating mtFASII disease.